Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “equal weight” rating reissued by equities research analysts at Barclays PLC in a research report issued on Saturday. They presently have a $450.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $400.00. Barclays PLC’s price target points to a potential downside of 12.78% from the stock’s current price.
Other analysts also recently issued research reports about the stock. Leerink Swann set a $448.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, March 28th. BTIG Research reissued a “buy” rating and set a $460.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, March 29th. UBS AG increased their target price on shares of Regeneron Pharmaceuticals from $435.00 to $446.00 and gave the stock a “buy” rating in a research report on Wednesday, March 29th. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 target price for the company in a research report on Thursday, April 27th. Finally, Vetr downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 target price for the company. in a research report on Monday, April 24th. One equities research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $467.38.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.00% on Friday, hitting $515.92. 617,665 shares of the stock traded hands. The stock has a market cap of $54.47 billion, a price-to-earnings ratio of 62.45 and a beta of 1.67. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $543.55. The firm’s 50-day moving average price is $493.24 and its 200-day moving average price is $413.36.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.50 by $0.42. The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The company’s revenue was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.57 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals will post $12.77 EPS for the current fiscal year.
In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 9,295 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $458.14, for a total value of $4,258,411.30. Following the sale, the chairman now directly owns 414,156 shares of the company’s stock, valued at $189,741,429.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael S. Brown sold 3,000 shares of the stock in a transaction on Friday, May 12th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the sale, the director now directly owns 3,000 shares in the company, valued at $1,350,000. The disclosure for this sale can be found here. Insiders sold 59,396 shares of company stock worth $28,484,734 over the last ninety days. 10.40% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the company. Korea Investment CORP raised its stake in shares of Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares in the last quarter. FNY Managed Accounts LLC bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at $140,000. Alpha Windward LLC raised its stake in shares of Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares in the last quarter. Wendell David Associates Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at $204,000. Finally, Welch & Forbes LLC bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at $211,000. 66.87% of the stock is currently owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
